Treatment of Fabry patients greater than 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0.2 mg/kg) Fabrazyme® (agalsidase beta) or Replagal® (agalsidase alfa)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2005
This article has no abstract
Epistemonikos ID: 230c298764dab05c3da702cab14d52497a4deb4e
First added on: Jan 17, 2025